Racializing drug design: Implications if pharmacogenomics for health disparities

American Journal of Public Health

Volumn 95, Issue 12, 2005, Pages 2133-2138

  Lee, Sandra Soo Jin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NEW DRUG;

CAUSE OF DEATH; CLINICAL PRACTICE; DRUG DESIGN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; ETHICS; FOOD AND DRUG ADMINISTRATION; GENE MAPPING; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH STATUS; HUMAN; HUMAN GENOME; MEDICAL RESEARCH; PHARMACOGENOMICS; PUBLIC HEALTH; RACE DIFFERENCE; REVIEW; SOCIAL ASPECT; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH;

CONTINENTAL POPULATION GROUPS; DRUG DESIGN; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACOGENETICS; UNITED STATES;

EID: 28444486917     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2005.068676     Document Type: Review

References (39)

1. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001;19(12):491-496.
2. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet. 2003;4:937-947.
3. Lindpaintner K. Pharmacogenetics and the future of medical practice. J Mol Med. 2003;81(3):141-153.
4. Taylor RE. Pharmacological and cultural considerations in alcohol treatment clinical trials: issues in clinical research related to race and ethnicity. Alcohol Clin Exp Res. 2003;27: 1345-1348.
5. Lee SSJ. Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am J Pharmacogenomics. 2003;3:385-292.
6. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med. 2003;348:1166-1170.
7. Sankar P. MEDLINE definitions of race and ethnicity and their application to genetic research. Nat Genet. 2003: 34(2):119, discussion 120.
8. Mordini E. Ethical considerations on pharmacogenomics. Pharmacol Res. 2004;49:375-379.
9. Kalow W. Pharmacogenetics and personalised medicine. Fundam Clin Pharmacol. 2002;16:337-342.
10. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J. 2003; 3(1):14-16.
11. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5(7):895-931.
12. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29(3): 192-209.
13. Stephens EA, Taylor JA, Kaplan N, et al. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics. 1994; 4(4):185-192.
14. Lazarou J, Pomeranz, BH, Corey PN. Incidence of adverse reactions on hospitalized patients. A meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205.
15. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:192-199.
16. March R, Cheeseman K, Doherty M. Pharmacogenomics-legal, ethical and regulatory considerations. Pharmacogenomics. 2001;2(4):317-327.
17. Veenstra D, Higashi MK, Phillips KA Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000; 2(3):E29.
18. Mehl B, Santell J. Projecting future drug expenditures-2000. Am J Health Syst Pharm. 2000;57(2):129-138.
19. Tollman P, Guy P, Altshuler J, Flanagan A, Steiner M. A Revolution in R&D: How Genomics and Genetics Are Transforming the Biopharmaceutical industry. Boston, Mass: Boston Consulting Group; 2001.
20. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost of illness model. Arch Intern Med 1995; 155:1949-1956.
21. Jones JK. Pharmacogenetics and pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2001;10:457-461.
22. International HapMap Project. Available at: http://www.hapmap.org/ hapmappopulations.html.en. Accessed March 28, 2005.
23. Hinds D, Stuve L, Nilsen G, et al. Whole-genome patterns of common DNA variation in three human populations. Science. 2005;307(5712): 1052-1053.
24. Satel SL. PC, MD: How Political Correctness Is Corrupting Medicine. New York, NY: Basic Books; 2000.
25. Satel S. I am a racially profiling doctor. New York Times Magazine. May 5, 2002:56. Available at http://www.sallysatelmd.com/html/a=nytimes3.html. Accessed on November 2, 2005.
26. Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health. 2003;93:2067-2073.
27. Anderson KO, Mendoza TR, Payne R, et al. Pain education for underserved minority cancer patients: a randomized controlled trial. J Clin Oncol. 2004;22: 4918-4925.
28. Kahn J. How a drug becomes "ethnie": law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics, 2004;4: 1-46.
29. Mancineffi L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci. 2000;2(1):E4.
30. Schwartz RM. Racial profiling in medicine. N Engl J Med 2001;344: 1392-1393.
31. Risen N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 2002;3(7):comment 2007.
32. Smedley B, Stith A, Nelson A. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: Institute of Medicine, National Academies Press; 2003.
33. Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J. 2003;3(4):194-196.
34. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov. 2002;1:300-308.
35. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet. 2004;5:663-669.
36. Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med. 2004;82(1):21-30.
37. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. QJM. 2000;93(7):391-423.
38. Rai AK. Pharmacogenomic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Soc Philos Policy. 2002;19(2):246-270.
39. FDA guidance for industry: pharmacogenomic data submissions. March 2005. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed September 3, 2005.